Oncology pharmacy
Showing 1 - 25 of 2,776
Malignant Digestive System Tumor Trial in Atlanta (Fluorouracil, Leucovorin, Oxaliplatin)
Recruiting
- Malignant Digestive System Neoplasm
- Fluorouracil
- +2 more
-
Atlanta, Georgia
- +2 more
Dec 12, 2022
Stasis Dermatitis Trial in United States (crisaborole ointment, vehicle ointment)
Completed
- Stasis Dermatitis
- crisaborole ointment
- vehicle ointment
-
El Segundo, California
- +3 more
Apr 1, 2022
Metastatic Colon Cancer Trial in Italy, Romania, Spain (AI)
Not yet recruiting
- Metastatic Colon Cancer
- AI
-
Firenze, Italy
- +5 more
May 30, 2022
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast
Active, not recruiting
- HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
- PF-06873600
- +2 more
-
Birmingham, Alabama
- +54 more
Nov 21, 2022
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or
Completed
- Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
- Avelumab Phase 1b
- +3 more
-
Fayetteville, Arkansas
- +57 more
Jan 18, 2023
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma Trial in United States
Active, not recruiting
- Non-small-cell Lung Cancer
- +5 more
- PF-07209960
-
Duarte, California
- +11 more
Oct 10, 2022
NSCLC Trial in Worldwide (Sasanlimab Prefilled syringe, Encorafenib, Binimetinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Sasanlimab Prefilled syringe
- +5 more
-
Duarte, California
- +96 more
Jan 18, 2023
Ovarian Cancer Trial in Worldwide (Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by
Completed
- Ovarian Cancer
- Chemotherapy + avelumab followed by avelumab + talazoparib
- +2 more
-
Phoenix, Arizona
- +71 more
Jul 21, 2022
Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer Trial in United States (PF-07104091 monotherapy dose escalation,
Recruiting
- Small Cell Lung Cancer
- +4 more
- PF-07104091 monotherapy dose escalation
- +8 more
-
Clive, Iowa
- +22 more
Apr 26, 2022
Breast Cancer Trial in Worldwide (Enzalutamide, exemestane, Placebo (for enzalutamide))
Chronic Myelogenous Leukemia - Chronic Phase Trial (asciminib)
Recruiting
- Chronic Myelogenous Leukemia - Chronic Phase
-
Birmingham, Alabama
- +25 more
Jan 10, 2023
Breast Tumors Trial in Worldwide (PD-0332991, Letrozole, Placebo)
Active, not recruiting
- Breast Neoplasms
- PD-0332991
- +2 more
-
Bellflower, California
- +304 more
Dec 6, 2022
NSCLC, Pancreatic Cancer, Colorectal Cancer Trial in Canada, United States (PF-06946860, Placebo for PF-06946860)
Completed
- Non-small Cell Lung Cancer
- +9 more
- PF-06946860
- Placebo for PF-06946860
-
Little Rock, Arkansas
- +32 more
Dec 12, 2022
Primary Immune Thrombocytopenia Trial in Worldwide (PF-06835375)
Suspended
- Primary Immune Thrombocytopenia
- PF-06835375
-
Jacksonville, Florida
- +27 more
Jan 25, 2023
Breast Tumors Trial in Israel, Korea, Republic of, United States (Atezolizumab (MPDL3280A), an engineered anti-programmed
Active, not recruiting
- Breast Neoplasms
- Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
- +7 more
-
Birmingham, Alabama
- +26 more
Dec 21, 2022
Prostate Cancer Trial in Worldwide (Enzalutamide, Abiraterone, Placebo for Enzalutamide)
Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1 Trial in Worldwide (Avelumab, Talazoparib)
Active, not recruiting
- Locally Advanced or Metastatic Solid Tumors
- Genes, BRCA 1
-
Palo Alto, California
- +89 more
Jan 18, 2023
Urothelial Cancer Trial in Worldwide (Avelumab, Best Supportive Care, Following the planned interim analysis for this study:
Active, not recruiting
- Urothelial Cancer
- Avelumab
- +2 more
-
Aurora, Colorado
- +370 more
Oct 24, 2022
Breast Cancer Trial in Worldwide (Elacestrant, Standard of Care)
Active, not recruiting
- Breast Cancer
- Elacestrant
- Standard of Care
-
Tucson, Arizona
- +167 more
Jul 19, 2022